WHO warns antibiotic resistance worsening in Europe
The World Health Organization on Wednesday warned that common bacteria are increasingly resistant to frontline and even last‑resort antibiotics, and said the situation is worse than in 2019. The agency issued the alert with the European Centre for Disease Prevention and Control after reviewing progress toward targets to cut infections caused by resistant bacteria.
Instead of a five percent reduction target for infections from the hospital bacterium Klebsiella pneumoniae, they rose by an estimated 72 percent between 2019 and 2025, the agencies said. Infections with E. coli that are resistant to common antibiotics known as cephalosporins were set a 10 percent decrease target; instead, they increased by more than 16 percent.
WHO said that in about one in two countries in Europe, it found resistance to key antibiotics in at least half of samples of Klebsiella pneumoniae and another common bug, Acinetobacter. Dr. Marc‑Alain Widdowson, who heads health security for WHO/Europe, said that across many countries in the region, “the antibiotics doctors usually reach for first are failing against serious hospital infections.” When these treatments fail, doctors turn to stronger drugs known as carbapenems. “When those stop working too, what’s left is mostly a small group of last‑resort drugs that are often expensive and not available in every country,” he said.
WHO said patients whose first antibiotic does not work are more likely to die in hospital. The agency noted that of 51 countries analyzed, 16 still lack a standardized national approach and national coordination, which hampers efforts to overcome antimicrobial resistance.
Testing gaps add to the risk, WHO said. Where hospitals take limited blood cultures to find the germ causing an infection, clinicians frequently must pick an antibiotic without evidence it will be effective. WHO said this leaves patients at risk of starting on a treatment that will not be effective and leaves health systems “planning half‑blind,” since countries cannot see where resistance is spreading or whether their efforts are working. The agency said better testing would help give patients the right drug sooner and give countries a clearer view of the threat.
WHO noted one area of improvement. The agency said bloodstream infections due to drug‑resistant Acinetobacter are estimated to be about half of what they were at the peak levels recorded in 2021 during the COVID‑19 pandemic.